Chronic Myelomonocytic Leukemia Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Chronic Myelomonocytic Leukemia Market is segmented By Treatment (Chemotherapy, Hypomethylating Agents, Targeted Therapy, Stem Cell Transplantation), ....
Chronic Myelomonocytic Leukemia Market Size
Market Size in USD
CAGR6.4%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.4% |
| Market Concentration | Medium |
| Major Players | Immune-Onc Therapeutics, Stemline Therapeutics, Otsuka Pharmaceutical, Novartis, Merck Sharp & Dohme |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Chronic Myelomonocytic Leukemia Market Analysis
The chronic myelomonocytic leukemia market is estimated to be valued at USD 950.2 Mn in 2024 and is expected to reach USD 1462.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031. According to recent studies, prevalence of chronic myelomonocytic leukemia has increased by 1.5% annually over the past 5 years. Furthermore, ongoing R&D and clinical trials for novel combination therapies and targeted drugs for treatment of CML indicate promising growth opportunities for players in this market.